Revolution Medicines starts Phase 3 trial of drug combo for pancreatic cancer

October 5, 2026 8:01 AM

Revolution Medicines, Inc. (Nasdaq: RVMD) announced it has begun enrolling patients in RASolute 309, a global, randomized, open-label Phase 3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found